Bottle of Lies: The Inside Story of the Generic Drug Boom

Analyze the global implications of the issues raised in the book. How do substandard drugs affect public health, particularly in developing countries? What are the responsibilities of pharmaceutical companies in this context?

Some critics, such as Jeremy A. Greene in The Washington Post, have argued that Eban ignores or downplays the instances of corporate malpractice within the American and European brand-name pharmaceutical industries. Research one of these instances and compare it to the depiction of Ranbaxy’s practices. How are the cases different or similar?

Evaluate the accountability of pharmaceutical companies for the manufacturing and distribution of substandard drugs. What role should corporate responsibility play in the pharmaceutical industry?

Examine the impact of substandard drugs on patient safety and the erosion of public trust in the pharmaceutical industry. How can trust be restored, and what measures can be taken to prioritize patient well-being?

Explore the role of whistleblowers in uncovering malpractices within the pharmaceutical industry. What challenges do whistleblowers face, and what protections should be in place to encourage transparency?

Investigate the economic factors that contribute to the production of substandard generic drugs. How do pricing pressures and market competition impact the quality of medications?

Compare the manufacturing standards and quality control measures between generic and brand-name drugs. What are the implications for patient outcomes, and how can these disparities be addressed?

Discuss the role of governments in addressing the issues outlined in Bottle of Lies. What policies and interventions can be implemented to safeguard the quality of generic drugs and protect public health? How can regulatory frameworks be improved to prevent the issues highlighted in the book?